GTS Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

GTS Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$776K	Sell	1,738 -884	-34%	-$412K	0.03%	498
2025 Q4	$1.19M	Sell	2,622 -3,112	-54%	-$1.34M	0.04%	379
2025 Q3	$2.25M	Buy	5,734 +4,086	+248%	+$1.71M	0.09%	183
2025 Q2	$734K	Sell	1,648 -418	-20%	-$193K	0.03%	487
2025 Q1	$1M	Sell	2,066 -1,263	-38%	-$589K	0.04%	392
2024 Q4	$1.34M	Sell	3,329 -1,158	-26%	-$537K	0.07%	239
2024 Q3	$2.09M	Buy	4,487 +2,487	+124%	+$1.19M	﹤0.01%	1551
2024 Q2	$937K	Buy	2,000 +1,413	+241%	+$613K	﹤0.01%	2104
2024 Q1	$245K	Sell	587 -5,744	-91%	-$2.43M	﹤0.01%	3171
2023 Q4	$2.58M	Buy	+6,331	New	+$2.34M	﹤0.01%	1471

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GTS Securities's VRTX Position: Q1 2026 in Review

GTS Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2026, selling an estimated $412K and leaving 1,738 shares worth $776K. The position accounts for 0.03% of the portfolio, ranked #498.

GTS Securities first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.58M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

GTS Securities held 1,738 shares of Vertex Pharmaceuticals worth $776K as of Q1 2026.
GTS Securities sold 884 Vertex Pharmaceuticals shares in Q1 2026, an estimated $412K.
Vertex Pharmaceuticals made up 0.03% of GTS Securities's portfolio in Q1 2026, its #498 holding.
GTS Securities first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
GTS Securities's Vertex Pharmaceuticals position peaked at $2.58M in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.